FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2867-2869 December 30, 2004 Number 27 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Gasche, Y. PubMed Citation

The response to many drugs in common use varies greatly among patients. After the intake of identical doses of a given agent, some patients may have clinically significant adverse effects, whereas others may have no therapeutic response. Some of this diversity in rates of response can be ascribed to differences in the rate of drug metabolism, particularly by the cytochrome P-450 superfamily of enzymes. Ten isoforms of cytochrome P-450 are responsible for the oxidative metabolism of most drugs, each having selective yet overlapping substrate specificity. Variability among patients in the activity of these enzymes reflects a complex interaction between environmental . . . [Full Text of this Article]

Source Information

From the Division of Medicine, Hadassah University Hospital, Ein Kerem, Jerusalem, Israel.

This article has been cited by other articles:

• Ginosar, Y., Davidson, E. M., Meroz, Y., Blotnick, S., Shacham, M., Caraco, Y. (2009). Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic-pharmacodynamic study. Br J Anaesth 103: 420-427 [Abstract] [Full Text]  
• Casner, P. R. (2005). The Effect of CYP2D6 Polymorphisms on Dextromethorphan Metabolism in Mexican Americans. J Clin Pharmacol 45: 1230-1235 [Abstract] [Full Text]